Reducing Cytotoxic Drug Exposure in Healthcare: Approaches and Challenges to Determining Cleaning Effectiveness. (205) P. Chua, Q. Danyluk, Fraser Health,
Burnaby, BC, Canada; W. Chu, University of British Columbia, Vancouver, BC, Canada; C. Hon, Vancouver Coastal Health, Vancouver, BC, Canada; G. Astrakianakis, Occupational Health and Safety Agency for Healthcare in BC, Vancouver, BC, Canada.

Hazardous By-Product Created Due to Cleaning Antineoplastic Contamination with Household Bleach. (206) C. Barzan, W. Chu, School of Environmental Health,
Vancouver, BC, Canada.

Preventive Measures and Medical Surveillance for Healthcare Workers Exposed to Antineoplastic and Other Hazardous Drugs. (207) M. Zaidi, S. Wasti, Sheikh Khalifa
Medical City, Abu Dhabi, United Arab Emirates; M. Zaidi, Public Health Agency of Canada, Ottawa, ON, Canada.

Development of Qualitative and Quantitative Measures for Pentamidine Aerosol in the Healthcare Environment. (208) D. Krageschmidt, J. Nesbitt, Mayo Clinic, Rochester, MN.

Decommissioning of a Beta-Lactam Pharmaceutical Development Facility. (209) D. Calhoun, Affygility Solutions, LLC, Lafayette, CO.

Case Study: Walking and Standing in Hospital Bedside Nursing Personnel. (210) T. Fuller, Environmental Performance Group, Boston, MA; E. Bain, Massachusetts
Nurse's Association, Canton, MA.

Strategic Planning for Bioterrorism in the Healthcare Industry. (211) J. Koerner, OSHA, Washington, DC.

Best Practices for Environment of Care Risk Assessment in Healthcare Organizations. (212) Y. Wang, Kaiser Permanente, Oakland, CA.